Opinion

Video

Timeline of Enfortumab Vedotin in UC: From Previously Treated UC to Frontline Therapy

Author(s):

Thomas Powles MBBS, MRCP, MD

Thomas Powles, MBBS, MRCP, MD, discusses how antibody-drug conjugates have demonstrated improvement over chemotherapy. Data from the EV-301 trial shows that the antibody-drug conjugate enfortumab vedotin decreased the risk of death by 30% versus chemotherapy. Later trial data showed that treatment using enfortumab vedotin plus pembrolizumab (EV+P) reduced the risk of patient death by 53%.

Related Videos
1 expert in this video
Guru P. Sonpavde, MD
1 expert in this video
1 expert in this video
Guru P. Sonpavde, MD
Janaki Neela Sharma, MD
1 expert in this video
1 expert in this video
Related Content
The OncFive: Top Oncology Articles for the Week of 11/17
November 23rd 2024

The OncFive: Top Oncology Articles for the Week of 11/17

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Janaki Neela Sharma, MD
November 10th 2024

Sylvester Annual Oncology Update Highlights Different Perspectives in Bladder Cancer, Other Treatment Areas

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Janaki Neela Sharma, MD, on urothelial cancer
November 7th 2024

Enfortumab Vedotin Plus Pembrolizumab Leads to Shifts in Frontline Metastatic Urothelial Cancer Management

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27